Prolonged Cytopenia After Idecabtagene Vicleucel for Multiple Myeloma is Associated with Poor Overall Survival - PubMed
3 hours ago
- #Multiple Myeloma
- #CAR-T Therapy
- #Cytopenia
- Prolonged cytopenia after idecabtagene vicleucel (ide-cel) CAR-T therapy in multiple myeloma is linked to worse survival outcomes.
- Cytopenias at Day 30 post-infusion occur in 25% of patients and correlate with inferior progression-free survival (PFS) and overall survival (OS).
- Cytopenias at Day 100 are rare (2%) but significantly associated with poorer OS, though not with PFS.
- A high CAR-HEMATOTOX score (≥2) predicts cytopenias at Day 30.
- The study uses observational data from 821 patients treated between 2021 and 2023.
- Definitions of cytopenia are based on immune effector cell-associated hematotoxicity criteria for neutropenia and thrombocytopenia.